“We want to change patient care journeys”: Indegene partners with Tealium

By Maggie Lynch

- Last updated on GMT

© metamorworks / Getty Images
© metamorworks / Getty Images

Related tags Indegene Tealium Artificial intelligence AI Clinical trials

Indegene’s partnership with Tealium leverages AI-driven data strategy for life sciences companies to navigate the industry’s connected technology ecosystem.

With this partnership, we want to enable pharma brands to gain a rapid competitive advantage that drives brand engagement, sales, retention, and loyalty,”​ Vivek Ghai, senior vice president Indegene Enterprise Commercial, told us.

“With the combined capabilities of Indegene and Tealium, we want to change the way patient care journeys are currently thought and designed,”​ said Ghai. Through this collaboration the healthcare solutions company can provide industry stakeholders the ability to better understand the needs of patients in timely manner.

Manish Gupta, CEO of Indegene, previously told Outsourcing-Pharma​, “Indegene was founded on the premise of bringing medical expertise and technology together.”​ The company evolved to help life sciences organizations bring products to the market through “modern” medical and commercial capabilities and operations.

The partnership enables Tealium’s life sciences clients to leverage the Tealium for Pharma platform to collect data. The platform utilizes artificial intelligence (AI) driven data capabilities for company’s omnichannel customer experience (CX).

“Together, we [Indegene and Tealium] aim to fuel growth by delivering next-gen data strategy, connected digital landscape, accurate segmentation, omnichannel personalization, compliant consent data management, and nuanced measurements and insights,”​ Ghai added.

Jay Calvas, head of vertical products at Tealium stated, that the life sciences industry is uniquely complex because of its evolving ecosystem. Because of the unique challenges that the industry creates “robust customer data strategy is critical.”

Ghai explained that a customer data platform (CDP) can advance clinical trial execution by providing a “connected technology ecosystem” across patients, research sites, and sponsors.

“As the life sciences industry moves from multichannel to omnichannel, the customer is going to be at the center, making customer data collection imperative,”​ said Ghai.

He stated that healthcare is also moving toward self-service programs, that rely on improving customer experience and reducing data acquisition costs. The programs utilize interactive online portals to help generate more complete patient profiles.

Self-service programs are often incorporated into decentralized clinical trials (DCT)s. Since the COVID-19 pandemic, many researchers have leveraged DCTs. Ghai explained that, CDPs, like that bolstered by the partnership with Tealium can support the execution of decentralized trials (DCT) by integrating systems like mobile apps and telehealth check-ins and optimize trial cost.

Related topics Clinical Development

Related news

Follow us


View more